Where US peptide vendors actually get their powder.

The vial says a brand name. The powder inside it almost certainly crossed an ocean. Here is how the research peptide supply chain really works, why the FDA now detains GLP-1 imports by default, and how to run a real supplier check yourself in five minutes.

The shape of the chain

Peptide synthesis at commercial scale is real industrial chemistry — solid-phase synthesis lines, HPLC purification, lyophilization, solvent handling, clean rooms. That capacity is concentrated in pharmaceutical manufacturing hubs, and the largest concentration by far is in China, with meaningful capacity in India and Europe. A typical US research vendor does not run any of it. The vendor imports bulk lyophilized powder by the gram or kilogram, then fills vials, applies labels, and ships — sometimes with real quality steps in between, sometimes with none.

None of this is inherently scandalous. It is how most of the world's generic pharmaceuticals work too. The scandal potential lives in the gap between what the chain is and what the marketing says it is — and in this market, that gap is often the whole pitch. Which is why the questions that matter are structural: who synthesized it, are they real, are they registered, and did anyone test the finished vial in the vendor's own name [that last one is the COA question].

The event that changed the GLP lane: Import Alert 66-80

In September 2025, FDA stood up Import Alert 66-80 — "Detention Without Physical Examination of Glucagon-Like Peptide-1 Receptor Agonist Bulk Drug Substances." A major revision landed July 27, 2026. The mechanism deserves a careful read, because it inverts the default you probably assume:

• Detention is the default. All imported GLP-1 bulk drug substances can be detained without physical examination.
• The only exemption is the green list — firms that maintained an active FDA foreign establishment registration and handed FDA batch records, COAs, validation reports, and customer lists.
• The green list is 19 firms worldwide as of the July 2026 revision: twelve in China, two in India, and one each in Belgium, Canada, Denmark, Ireland, and Portugal.
• The names are redacted on the public page. Only countries and product codes are visible — you cannot simply read the list and match your supplier against it.

Two more details from the alert are worth quoting because they describe this market with unusual precision. FDA evaluated 48 GLP-1 API sites and found 21% noncompliant with basic drug-quality requirements. And the agency describes a specific evasion pattern it keeps encountering: "a pattern of sites that register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA's requests for records, and then deregister, all within a short period of time." Registration theater — put a real-looking FEI number on the sales deck, ship for a season, vanish before the records request lands. Enforcement in this lane is active: FDA issued a warning letter to a Harbin-based biotech in May 2026 over GLP-1 import violations.

What this means one step downstream — at your vendor

Import Alert 66-80 covers bulk API entering the country, not the finished research vial you buy. But every US vendor selling GLP-class research compounds sits directly downstream of it. A vendor whose upstream maker is green-listed has a stable, lawful import lane. A vendor whose upstream maker is not faces detained shipments — and the market's workarounds for that problem are exactly the red flags buyers keep being told to ignore:

• "100% delivery guarantee — full reship if lost or seized." A supplier pricing in seizures is telling you which side of the default they expect to land on.
• "Discreet packaging, no external labeling." Licensed API ships labeled with substance, lot, and manufacturer, and clears customs with a COA. Unlabeled is a posture, and it is not a quality posture.
• Crypto-only payment with a discount. Covered in depth in our payments report — the discount is the measured price of your chargeback rights.

The five-minute supplier check anyone can run

Here is the part that makes this article practical rather than atmospheric. The green list's names are redacted — but its precondition is public and searchable. The alert covers "registered foreign manufacturers," and green-list membership requires an active FDA foreign establishment registration with an FEI number. No registration, no green list. Registration is checkable by anyone, free, against two bulk files:

1. The establishment registration file. FDA publishes the Drug Establishments Current Registration Site data — roughly ten thousand rows, downloadable. Search the company name and its variants. A genuine API maker appears with a full street address, an FEI number, and an operation type of API manufacture.
2. The Drug Master File list. FDA's DMF list — about forty thousand rows — shows which firms have filed manufacturing dossiers. Serious API makers accumulate DMFs; a firm claiming years of pharma manufacturing with zero is telling on itself.

And the single question that separates every tier of this market: ask the supplier for an FEI number and a DMF reference. A real one supplies both on request, because both are ordinary credentials in legitimate pharmaceutical trade. Evasion, delay, or a photograph of an unrelated certificate answers the question just as clearly.

Field guide: reading a supplier the way an auditor would

One more pattern worth naming, because it recurs constantly: the quality spread is the fingerprint. When independent community testing of a "manufacturer" shows some compounds testing consistently strong while others from the same seller fail at high rates, that is the signature of a reseller aggregating different upstream factories — not one facility with one quality system. A real manufacturer's quality is correlated across its catalog. A trader's is not.

Why "US-made" is starting to matter — and what to demand of the claim

Import pressure on the GLP lane is pushing part of the market toward domestic synthesis and domestic fill, and "US-made" will increasingly appear as a selling point. Treat the claim exactly the way you treat a COA: as a checkable document, not a vibe. US drug establishments register with FDA in the same public file as foreign ones. A vendor claiming US synthesis should be able to say who synthesizes, and that name should resolve to a registered establishment. A vendor claiming US fill-and-finish is making a smaller claim — still meaningful for handling and lead times, but it is not a synthesis claim, and honest vendors keep the two distinct.

What we'd tell a friend

Buy from vendors who treat the supply chain as something to document rather than something to romance. The strongest vendors in this market can tell you, without flinching: where the powder originates, what arrives with it, and what testing happens after it becomes their lot — in their name, at a named lab. That last document is the one you can hold. Our 2026 COA audit ranks vendors on exactly that, and the buying fundamentals put the whole sequence in order.

FAQ

References

1. FDA Import Alert 66-80 — Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances — accessdata.fda.gov [original list September 2025; major revision July 27, 2026]
2. FDA, Drug Establishments Current Registration Site [downloadable registration file] — fda.gov
3. FDA, List of Drug Master Files — fda.gov
4. FDA warning letters database [GLP-1 import enforcement, 2026] — fda.gov

disclosure: inside your peptides may earn referral fees from vendor links, including the next lab. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.